Lineage Cell Therapeutics Inc
AMEX:LCTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lineage Cell Therapeutics Inc
AMEX:LCTX
|
US |
Intrinsic Value
The intrinsic value of Lineage Cell Therapeutics Inc (LCTX) under the Base Case is 0.0004 USD per share. Compared with the current market price of 0.99 USD, the stock appears Overvalued by 100% .
The intrinsic value is calculated using the DCF method. Net margin recovers from -436% last year to 30% by 2031. Revenue grows about -1% a year over the next five years. The forecast years subtract value, so the estimate rests entirely on the years after 2031.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Lineage Cell Therapeutics Does
Lineage Cell Therapeutics is a biotechnology company that develops cell-based medicines, with a focus on using living cells to replace or repair damaged tissue. Its main work is in regenerative medicine, especially programs for eye disease and spinal cord-related conditions. The company does not sell consumer products; it sells science, drug candidates, and development rights that could become future treatments.
- Headquarters
- United States of America US
- Employees
- 75
- IPO date
- Mar 5, 1992
Earnings Waterfall
Lineage Cell Therapeutics Inc
The intrinsic value for Lineage Cell Therapeutics Inc (LCTX) under the Base Case is 0.0004 USD.
Compared with the current market price of 0.99 USD, the stock appears Overvalued by 100% .